Known targets — ChEMBL curated mechanism
ADORA2AADORA2BPDE10APDE1APDE1BPDE1CPDE2APDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE6APDE6BPDE6CPDE6DPDE6GPDE6HPDE7APDE7BPDE8APDE8BPDE9A
The experimentally established mechanism targets of Pentoxifylline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B known ✓ | P29275 | 6/20 | 1.00 |
| ▸ | PDE4A known ✓ | P27815 | 2/20 | 1.00 |
| ▸ | PDE4B known ✓ | Q07343 | 1/20 | 1.00 |
| ▸ | PDE4C known ✓ | Q08493 | 1/20 | 1.00 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 1.00 |
| ▸ | TNF | P01375 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | ACHE | P22303 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 0.74 |
| ▸ | ESR1 | P03372 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentoxifylline SCHEMBL3986204 | 1.00 | ADORA2B (1.00) | ADORA2BTNFLMNACYP1A2NFKB1 | |
| SCHEMBL8150960 | 0.99 | ADORA2B (0.97) | ADORA2BTNFLMNACYP1A2NFKB1 | |
| SCHEMBL8686071 | 0.99 | ADORA2B (0.97) | ADORA2BTNFLMNACYP1A2NFKB1 | |
| SCHEMBL8687521 | 0.99 | ADORA2B (0.97) | ADORA2BTNFLMNACYP1A2NFKB1 | |
| SCHEMBL8686347 | 0.99 | ADORA2B (0.97) | ADORA2BTNFLMNACYP1A2NFKB1 | |
| SCHEMBL9123538 | 0.99 | ADORA2B (0.97) | ADORA2BTNFLMNACYP1A2NFKB1 | |
| SCHEMBL8687852 | 0.99 | ADORA2B (0.97) | ADORA2BTNFLMNACYP1A2NFKB1 | |
| SCHEMBL9123561 | 0.99 | ADORA2B (0.97) | ADORA2BTNFLMNACYP1A2NFKB1 | |
| Pentoxifylline SCHEMBL8140331 | 0.99 | ADORA2B (0.97) | ADORA2BTNFLMNACYP1A2NFKB1 | |
| SCHEMBL8696287 | 0.99 | ADORA2B (0.97) | ADORA2BTNFLMNACYP1A2NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 29062 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070931-A | Injection composition for lipolysis | 姜旼材 | 2026-05-22 | — | — | CN | claimed |
| US-20260138973-A1 | SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| US-20260137761-A1 | INJECTION COMPOSITION FOR LIPOLYSIS | KANG MIN JAE (KR) | 2026-05-21 | — | — | US | claimed |
| US-20260137680-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| US-20260132191-A1 | METHODS FOR MODULATING ACTIVITY OF IL-18 FOR TREATMENT OF CD4+ T CELL MEDIATED AUTOIMMUNITY AND IMMUNOPATHOLOGY | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2026-05-14 | — | — | US | claimed |
| US-12617762-B2 | Carboxy derivatives with antiinflamatory properties | SITRYX THERAPEUTICS LIMITED (GB) | 2026-05-05 | — | — | US | claimed |
| US-12616691-B2 | Use of fatty acid oxidation inhibitors as antimicrobials | WASHINGTON UNIVERSITY IN ST. LOUIS (US) | 2026-05-05 | — | — | US | claimed |
| US-20260115161-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | LAMINAR PHARMACEUTICALS S A (ES) | 2026-04-30 | — | — | US | claimed |
| WO-2026090251-A1 | METHODS FOR IMPROVING TREATMENT OUTCOMES IN PATIENTS UNDERGOING ULTRAFILTRATION | PROLETARIAT THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-4636507-A | Host defense mechanism enhancement | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1987-01-13 | — | — | US | claimed |
| CN-85106465-A | A kind of preparation process of pharmaceutical preparation | — | 1986-10-29 | — | — | CN | claimed |
| US-4612194-A | VITAMIN E, VASODILATORS | ROSHDY ISMAIL | 1986-09-16 | — | — | US | claimed |
| EP-0069958-B1 | Method for the preparation of gastro compatible pharmaceutical forms of xanthine derivatives. | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-04-02 | — | — | EP | claimed |
| EP-0169466-A2 | Mixture of xanthin derivatives and O-acetyl-salicylic acid, or their pharmacologically acceptable salts, and its use | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-01-29 | — | — | EP | claimed |
| US-4542011-A | PROTECTIVE COATINGS | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-09-17 | — | — | US | claimed |
| US-4511557-A | CALF'S BLOOD DIAYSATE AS VASODILATION POTENTIATOR | GAURI KAILASH KUMAR (DE) | 1985-04-16 | — | — | US | claimed |
| EP-0101963-A1 | Orally administrable galenic forms of soluble dimethylxanthine derivatives | LABORATOIRES HOECHST S.A. (FR) | 1984-03-07 | — | — | EP | claimed |
| US-4383997-A | N-CINNAMYL-N'-BENZHYDRYLPIPERAZINE | RHEOTECH LABS, INC. | 1983-05-17 | — | — | US | claimed |
| US-4189469-A | Pharmaceutical compositions | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-02-19 | — | — | US | claimed |